Given the decreasing TSH (down to 0.38) and low free T4 (0.43 ng/dL) while on levothyroxine 37.5 µg and liothyronine 5 µg daily, should the thyroid medication regimen be adjusted?

Reduce Your Current Thyroid Medication Dose Immediately

Your current regimen is causing biochemical overtreatment with a suppressed TSH of 0.38-0.664 µIU/mL and critically low free T4 of 0.43 ng/dL, indicating excessive T3 relative to T4 replacement. You need to decrease the liothyronine (T3) dose and increase the levothyroxine (T4) dose to restore proper thyroid hormone balance.

The Core Problem: T3-Predominant Overtreatment

Your lab pattern reveals a classic problem with combination T4/T3 therapy:

• Suppressed TSH (0.38 → 0.88 → 0.664 µIU/mL) - well below the normal range lower limit of 0.27-0.4 mIU/L
• Inappropriately low free T4 (0.43 ng/dL) - this is critically low and concerning
• Relatively preserved free T3 (2.18-2.50 pg/mL range recently)

This pattern indicates your T3 dose is suppressing TSH production while simultaneously suppressing your body's conversion of T4 to T3, leaving you with inadequate T4 levels. The TSH is being driven down by the exogenous T3, not by adequate overall thyroid hormone replacement 1.

Why This Matters for Your Health

The principal adverse consequences of overtreatment are cardiovascular (atrial fibrillation, especially in elderly), skeletal (accelerated bone loss in postmenopausal women), and possibly mood disturbances 1. Your suppressed TSH puts you at risk for these complications even though your T4 is paradoxically low.

Recommended Medication Adjustment

Immediate Changes:

1. Reduce liothyronine from 5 mcg to 2.5 mcg daily (or discontinue entirely)
2. Increase levothyroxine from 37.5 mcg to 50-62.5 mcg daily

The goal is to shift toward more T4-predominant replacement, which allows your body to regulate T3 conversion naturally rather than having exogenous T3 suppress your pituitary feedback 1.

Target Goals:

• TSH: 0.3-2.0 mIU/L (some guidelines accept 0.1-0.3 mIU/L in select cases, but not fully suppressed) 2
• Free T4: Mid-to-upper normal range for your laboratory's reference interval
• Free T3: Within normal range (not elevated)

The Evidence Behind This Recommendation

Levothyroxine monotherapy should remain the standard of care for treating hypothyroidism 3. The 2014 American Thyroid Association guidelines found no consistently strong evidence for superiority of combination T4/T3 therapy over levothyroxine alone in improving health outcomes 3.

Your current T4:T3 ratio is approximately 7.5:1 by weight (37.5 mcg T4 to 5 mcg T3). Natural thyroid hormone has a ratio of approximately 4:1 1, but when given as replacement therapy, most patients do well on T4 monotherapy because the body converts T4 to T3 as needed. Your suppressed TSH with low T4 suggests the exogenous T3 is interfering with this natural regulation.

The 2023 British Thyroid Association consensus acknowledges that some patients may warrant a trial of combination therapy, but emphasizes that levothyroxine doses should be optimized first, aiming for TSH 0.3-2.0 mU/L for 3-6 months before assessing therapeutic response 2. You haven't achieved this yet.

Monitoring Plan

Recheck TSH and free T4 in 4-8 weeks after any dose adjustment 1. With smaller dose changes, it may take 8 weeks or longer for TSH to plateau 1.

• If TSH remains suppressed after increasing T4 and reducing T3, consider discontinuing T3 entirely
• Once stable, monitor every 6 months, then annually 1
• Take medication consistently 30-60 minutes before breakfast on an empty stomach 1

Critical Pitfalls to Avoid

1. Don't continue with suppressed TSH long-term - this increases cardiovascular and bone risks 1
2. Don't assume low T4 means you need more T4 while keeping T3 the same - the T3 is causing the problem
3. Don't take thyroid medication with calcium, iron, antacids, or proton pump inhibitors - separate by at least 4 hours 4
4. Don't make dose changes more frequently than every 4-8 weeks - thyroid levels need time to stabilize 1

Why Combination Therapy Often Fails

Multiple randomized controlled trials show no benefit of T4/T3 combination over T4 monotherapy 2, 5, 3. A 2016 crossover study found that combination therapy yielded significantly lower free T4 levels with no changes in TSH or T3, and more patients on combination therapy had elevated T3 levels (15% vs 3%) with no clear clinical benefit 5.

Your lab pattern perfectly illustrates this problem: suppressed TSH, low T4, and the T3 preventing proper homeostatic regulation.

The ratio of T4 to T3 in your current regimen is inappropriate for most patients. Even desiccated thyroid extract, which has a 4:1 ratio, often causes similar problems with T3-predominant effects 1.

If Symptoms Persist After Optimization

Only after achieving stable TSH 0.3-2.0 mIU/L on optimized levothyroxine monotherapy for 3-6 months should persistent symptoms be attributed to inadequate thyroid replacement 2. At that point, other causes must be excluded before considering any return to combination therapy.

Your immediate priority is correcting the biochemical overtreatment to prevent cardiovascular and skeletal complications while establishing proper T4 replacement.